Sign in Sign up for free

Last updated: 14 June 2024 at 5:46pm EST

Theresa Heggie Net Worth




The estimated Net Worth of Theresa Heggie is at least $569 Thousand dollars as of 12 June 2024. Ms. Heggie owns over 6,698 units of Biocryst Pharmaceuticals stock worth over $408,546 and over the last 6 years she sold BCRX stock worth over $40,925. In addition, she makes $119,713 as Independent Director at Biocryst Pharmaceuticals.

Ms. Heggie BCRX stock SEC Form 4 insiders trading

Theresa has made over 2 trades of the Biocryst Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 6,698 units of BCRX stock worth $40,925 on 12 June 2024.

The largest trade she's ever made was selling 6,698 units of Biocryst Pharmaceuticals stock on 12 June 2024 worth over $40,925. On average, Theresa trades about 418 units every 60 days since 2018. As of 12 June 2024 she still owns at least 52,852 units of Biocryst Pharmaceuticals stock.

You can see the complete history of Ms. Heggie stock trades at the bottom of the page.





Theresa Heggie biography

Theresa M. Heggie serves as Independent Director of the Company. She was appointed to the Board in December 2018. Ms. Heggie currently serves as Senior Vice President, head of Europe, Canada, Middle East and Africa for Alnylam Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company. From May 2016 to April 2017, she served as a non-executive director of Swedish Orphan Biovitrum AB, an international specialty biopharmaceutical company dedicated to rare diseases. From June 2013 to March 2016, Ms. Heggie sareved as Chief Strategy and Marketing Officer for Bupa, an international healthcare group. Prior to June 2013, Ms. Heggie served in senior commercial and operating roles at Shire plc, a global specialty biopharmaceutical company, including Senior Vice President, Global Commercial Operations for the rare disease business. Prior to that, Ms. Heggie had responsibility over EMEA rare disease and served as Chief Executive Officer of Jerini AG, a pharmaceutical company, following Shire’s acquisition of the company, and its lead asset, Firazyr®, for the treatment of hereditary angioedema. Prior to joining Shire, Ms. Heggie spent more than 20 years in a broad range of increasingly senior commercial positions at Janssen Pharmaceuticals and Baxter Healthcare. Ms. Heggie holds a Bachelor of Science degree from Cornell University. Ms. Heggie’s extensive commercial experience in the industry, especially her rare disease commercial experience, provide valuable knowledge and insight to the Board.

What is the salary of Theresa Heggie?

As the Independent Director of Biocryst Pharmaceuticals, the total compensation of Theresa Heggie at Biocryst Pharmaceuticals is $119,713. There are 13 executives at Biocryst Pharmaceuticals getting paid more, with Jon Stonehouse having the highest compensation of $2,284,300.



How old is Theresa Heggie?

Theresa Heggie is 59, she's been the Independent Director of Biocryst Pharmaceuticals since 2018. There are 10 older and 11 younger executives at Biocryst Pharmaceuticals. The oldest executive at Biocryst Pharmaceuticals Inc. is Robert Ingram, 77, who is the Independent Chairman of the Board.

What's Theresa Heggie's mailing address?

Theresa's mailing address filed with the SEC is 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703.

Insiders trading at Biocryst Pharmaceuticals

Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi..., and Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.



What does Biocryst Pharmaceuticals do?

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.



What does Biocryst Pharmaceuticals's logo look like?

Biocryst Pharmaceuticals Inc. logo

Complete history of Ms. Heggie stock trades at Biocryst Pharmaceuticals

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
12 Jun 2024 BCRX Biocryst Pharmaceuticals Inc. Theresa Heggie
Director
 Sale 6,698 $6.11 $40,925
12 Jun 2024
52,852 ↗
18 Nov 2019 BCRX Biocryst Pharmaceuticals Inc. Theresa Heggie
Director
 Buy 5,000 $1.45 $7,250
18 Nov 2019
6,672 ↗


Biocryst Pharmaceuticals executives and stock owners

Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include: